SCHEMBL311630

SCHEMBL311630

Fc1ccccc1COc1ccc(Br)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 6/20 0.65
PARP15 Q460N3 2/20 0.59
PARP10 Q53GL7 2/20 0.59
PARP14 Q460N5 1/20 0.59
NPC1 O15118 3/20 0.56
RAB9A P51151 3/20 0.56
CASP3 P42574 1/20 0.56
SENP8 Q96LD8 1/20 0.56
SENP7 Q9BQF6 1/20 0.56
SENP6 Q9GZR1 1/20 0.56
IDO1 P14902 2/20 0.50
SCN3A Q9NY46 2/20 0.50
NFKB1 P19838 1/20 0.50
NFKB2 Q00653 1/20 0.50
RELA Q04206 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
RECQL P46063 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
PKM P14618 1/20 0.50
TSHR P16473 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29385396 1.00 MAOB (0.65) MAOBPARP15PARP10PARP14NPC1
SCHEMBL12423201 0.85 MAOB (0.69) MAOBPARP15PARP10PARP14NPC1
SCHEMBL17644774 0.84 MAOB (0.68) MAOBPARP15PARP10PARP14NPC1
SCHEMBL20360954 0.84 MAOB (0.47) MAOBPARP15PARP10PARP14NPC1
SCHEMBL483569 0.83 MAOB (0.48) MAOBPARP15PARP10PARP14NPC1
SCHEMBL3625841 0.83 MAOB (0.67) MAOBPARP15PARP10PARP14NPC1
Hydrochloric Acid SCHEMBL28551904 0.82 MAOB (0.69) MAOBPARP15PARP10PARP14NPC1
SCHEMBL4229059 0.82 MAOB (0.71) MAOBPARP15PARP10PARP14NPC1
SCHEMBL17804382 0.81 MAOB (0.65) MAOBPARP15PARP10PARP14NPC1
SCHEMBL21340831 0.81 MAOB (0.65) MAOBPARP15PARP10PARP14NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107722996-B Polymerizable liquid crystal compound and preparation method and application thereof 北京八亿时空液晶科技股份有限公司 2023-06-09 CN disclosed
US-20220177426-A1 PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES BIOGEN MA INC. 2022-06-09 US disclosed
EP-3953329-A1 PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES Biogen MA Inc. (US) 2022-02-16 EP disclosed
CN-114026066-A Process for preparing alpha-carboxamide pyrrolidine derivatives 生物基因麻省公司 2022-02-08 CN disclosed
CN-107699252-B Polymeric liquid crystal compound and preparation method and application thereof 北京八亿时空液晶科技股份有限公司 2021-09-07 CN disclosed
WO-2020210485-A1 PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES BIOGEN MA INC. (US) 2020-10-15 WO disclosed
WO-2020210485-A1 PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES BIOGEN MA INC. (US) 2020-10-15 WO disclosed
EP-2461807-A1 CO-THERAPY FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS Convergence Pharmaceuticals Limited (GB) 2012-06-13 EP disclosed
EP-1934177-B1 PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS GLAXO GROUP LTD (GB) 2012-05-02 EP disclosed
EP-1934177-B1 PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS GLAXO GROUP LTD (GB) 2012-05-02 EP disclosed
WO-2008090116-A1 NOVEL PHARMACEUTICAL COMPOSITIONS GLAXO GROUP LIMITED (GB) 2008-07-31 WO disclosed
EP-1943216-A1 PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS GLAXO GROUP LIMITED (GB) 2008-07-16 EP disclosed
EP-1934177-A1 PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS GLAXO GROUP LIMITED (GB) 2008-06-25 EP disclosed
WO-2007042239-A1 PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS GLAXO GROUP LIMITED (GB) 2007-04-19 WO disclosed
WO-2007042239-A1 PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS GLAXO GROUP LIMITED (GB) 2007-04-19 WO disclosed
WO-2007042240-A1 QUATERNARY ALPHA-AMINOCARBOXAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS GLAXO GROUP LIMITED (GB) 2007-04-19 WO disclosed
WO-2007042250-A1 PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS GLAXO GROUP LIMITED (GB) 2007-04-19 WO disclosed
WO-2007042250-A1 PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS GLAXO GROUP LIMITED (GB) 2007-04-19 WO disclosed
EP-0394906-B1 Liquid crystalline composition MERCK PATENT GMBH (DE) 1995-12-20 EP disclosed
EP-0394906-A2 Liquid crystalline composition MERCK PATENT GmbH (DE) 1990-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220177426-A1 PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES CPS1, PCCA, ALDH18A1 MAOB 114/4885PARP15 56/4885PARP10 729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.